KPMG report: Transfer pricing considerations in the age of precision medicine

A KPMG report concerning transfer pricing considerations in the age of precision medicine

A KPMG report concerning transfer pricing considerations in the age of precision medicine

Precision medicine is fundamentally transforming the healthcare and life sciences industry, and becoming increasingly important to academic medical centers, diagnostics and biopharma companies, laboratories, healthcare providers, payers, and data providers. Medicine is moving from a ‘‘one-size-fits-all’’ mentality to an approach that diagnoses and treats disease tailored to an individual’s genes, environment, and lifestyle. The importance of precision medicine is moving beyond the vanguard of oncology to other disease areas such as neurology and autoimmune diseases.

Chimeric antigen receptor T-cell (CAR T) therapy, a type of cell and gene therapy, represents one of the most exciting and high-profile areas of precision medicine as it has had curative outcomes for patients in some cases. CAR T products are currently marketed and are being investigated in clinical trials for many diseases when patients have no other treatment options. Many big pharma companies have made significant investments into their CAR T capabilities in recent years—from outright mergers and acquisitions (M&As) in order to access technologies and platforms, to large capital investments in manufacturing facilities.

Read an October 2022 report* [PDF 531 KB] prepared KPMG LLP that discusses the disruption caused by CAR T to standard business models in the life sciences industry and its implications for transfer pricing.

*This article originally appeared in Tax Management International Journal (7 October 2022) and is provided with permission.


The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization. KPMG International Limited is a private English company limited by guarantee and does not provide services to clients. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm. The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation. For more information, contact KPMG's Federal Tax Legislative and Regulatory Services Group at: + 1 202 533 3712, 1801 K Street NW, Washington, DC 20006.